Comparison of Twin and Autologous Transplants for Multiple Myeloma

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 10, 2008, Pages 1118-1124

  Bashey, Asad ^a   Pérez, Waleska S ^b   Zhang, Mei Jie ^b   Anderson, Kenneth C ^c   Ballen, Karen ^d   Berenson, James R ^e   To, L Bik ^f   Fonseca, Rafael ^g   Freytes, César O ^h   Gale, Robert Peter ⁱ   Gibson, John ^j   Giralt, Sergio A ^k   Kyle, Robert A ^l   Lazarus, Hillard M ^m   Maharaj, Dipnarine ⁿ   McCarthy, Philip L ^o   Milone, Gustavo A ^p   Nimer, Stephen ^q   Pavlovsky, Santiago ^p   Reece, Donna E ^r   Schiller, Gary ^s   Vesole, David H ^t   Hari, Parameswaran ^b   more..

^a BMT Group of Georgia   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

^f INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^g MAYO CLINIC   (United States)

^h UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

ⁱ CELGENE CORPORATION   (United States)

^j ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^l MAYO CLINIC ROCHESTER   (United States)

^m UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

ⁿ South Florida Bone Marrow Stem Cell Transplant Institute   (United States)

^o ROSWELL PARK CANCER INSTITUTE   (United States)

^p Fundacion para Combatir La Leucemia   (Argentina)

^q MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^r PRINCESS MARGARET HOSPITAL   (Canada)

^s UNIVERSITY OF CALIFORNIA   (United States)

^t ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

more..

Author keywords

Autotransplant; Graft versus myeloma; Multiple myeloma; Twin

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; INTERFERON; INTERLEUKIN 2; MELPHALAN; THALIDOMIDE;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; FEMALE; GRAFT RECIPIENT; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PROBABILITY; PROPORTIONAL HAZARDS MODEL; RELAPSE; TREATMENT OUTCOME;

ADULT; AGED; ANALYSIS OF VARIANCE; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, ISOGENEIC; TWINS, MONOZYGOTIC;

EID: 51649085791     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.07.007     Document Type: Article

References (22)

1. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 (2003) 1875-1883
2. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335 (1996) 91-97
3. Mariette X., Fermand J.P., and Brouet J.C. Myeloma cell contamination of peripheral blood stem cell grafts in patients with multiple myeloma treated by high-dose therapy. Bone Marrow Transplant 14 (1994) 47-50
4. Henry J.M., Sykes P.J., Brisco M.J., To L.B., Juttner C.A., and Morley A.A. Comparison of myeloma cell contamination of bone marrow and peripheral blood stem cell harvests. Br J Haematol 92 (1996) 614-619
5. Vescio R.A., Han E.J., Schiller G.J., et al. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts. Bone Marrow Transplant 18 (1996) 103-110
6. Ladetto M., Omede P., Sametti S., et al. Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests. Exp Hematol 30 (2002) 529-536
7. Mateo G., Corral M., Almeida J., et al. Immunophenotypic analysis of peripheral blood stem cell harvests from patients with multiple myeloma. Haematologica 88 (2003) 1013-1021
8. Vogel W., Kopp H.G., Kanz L., and Einsele H. Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation. J Cancer Res Clin Oncol 131 (2005) 214-218
9. Cremer F.W., Kiel K., Wallmeier M., Goldschmidt H., and Moos M. A quantitative PCR assay for the detection of low amounts of malignant cells in multiple myeloma. Ann Oncol 8 (1997) 633-636
10. Galimberti S., Morabito F., Guerrini F., et al. Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. Br J Haematol 120 (2003) 405-412
11. Martinelli G., Terragna C., Lemoli R.M., et al. Clinical and molecular follow-up by amplification of the CDR-III IgH region in multiple myeloma patients after autologous transplantation of hematopoietic CD34+ stem cells. Haematologica 84 (1999) 397-404
12. Gupta D., Bybee A., Cooke F., et al. CD34+-selected peripheral blood progenitor cell transplantation in patients with multiple myeloma: tumour cell contamination and outcome. Br J Haematol 104 (1999) 166-177
13. Stewart A.K., Vescio R., Schiller G., et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 19 (2001) 3771-3779
14. Bensinger W.I., Demirer T., Buckner C.D., et al. Syngeneic marrow transplantation in patients with multiple myeloma. Bone Marrow Transplant 18 (1996) 527-531
15. Gahrton G., Svensson H., Bjorkstrand B., et al. Syngeneic transplantation in multiple myeloma-a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 24 (1999) 741-745
16. Bruno B., Rotta M., Patriarca F., et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl. J Med 356 (2007) 1110-1120
17. Bjorkstrand B.B., Ljungman P., Svensson H., et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 88 (1996) 4711-4718
18. Reynolds C., Ratanatharathorn V., Adams P., et al. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma. Bone Marrow Transplant 27 (2001) 801-807
19. Alici E., Bjorkstrand B., Treschow A., et al. Long-term follow-up of gene-marked CD34+ cells after autologous stem cell transplantation for multiple myeloma. Cancer Gene Ther 14 (2007) 227-232
20. Adams K.M., and Nelson J.L. Microchimerism: an investigative frontier in autoimmunity and transplantation. JAMA 291 (2004) 1127-1131
21. Lokhorst H.M., Schattenberg A., Cornelissen J.J., et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 18 (2000) 3031-3037
22. van de Donk N.W., Kroger N., Hegenbart U., et al. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 37 (2006) 1135-1141